New Potent SARS-CoV 3C-Like Protease Inhibitors Derived from Thieno[2,3-d]-pyrimidine Derivatives.
Identifieur interne : 000F72 ( Main/Exploration ); précédent : 000F71; suivant : 000F73New Potent SARS-CoV 3C-Like Protease Inhibitors Derived from Thieno[2,3-d]-pyrimidine Derivatives.
Auteurs : Amira S. Abd El-All [Égypte] ; Sanaa M Sh Atta [Égypte] ; Hanaa M F. Roaiah [Égypte] ; Enas M. Awad [Égypte] ; Mohamed M. Abdalla [Égypte]Source :
- Archiv der Pharmazie [ 1521-4184 ] ; 2016.
Descripteurs français
- KwdFr :
- Antiviraux (), Antiviraux (synthèse chimique), Cysteine endopeptidases (), Protéines virales (), Protéines virales (antagonistes et inhibiteurs), Pyrimidines (), Pyrimidines (synthèse chimique), Relation structure-activité, Sialidase (), Sialidase (antagonistes et inhibiteurs), Sous-type H3N2 du virus de la grippe A (enzymologie).
- MESH :
- antagonistes et inhibiteurs : Protéines virales, Sialidase.
- enzymologie : Sous-type H3N2 du virus de la grippe A.
- synthèse chimique : Antiviraux, Pyrimidines.
- Antiviraux, Cysteine endopeptidases, Protéines virales, Pyrimidines, Relation structure-activité, Sialidase.
English descriptors
- KwdEn :
- Antiviral Agents (chemical synthesis), Antiviral Agents (chemistry), Cysteine Endopeptidases (chemistry), Influenza A Virus, H3N2 Subtype (enzymology), Neuraminidase (antagonists & inhibitors), Neuraminidase (chemistry), Pyrimidines (chemical synthesis), Pyrimidines (chemistry), Structure-Activity Relationship, Viral Proteins (antagonists & inhibitors), Viral Proteins (chemistry).
- MESH :
- chemical , antagonists & inhibitors : Neuraminidase, Viral Proteins.
- chemical , chemical synthesis : Antiviral Agents, Pyrimidines.
- chemical , chemistry : Antiviral Agents, Cysteine Endopeptidases, Neuraminidase, Pyrimidines, Viral Proteins.
- enzymology : Influenza A Virus, H3N2 Subtype.
- Structure-Activity Relationship.
Abstract
2-Amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxamide (1) condensed with carbaldehydes 2a,b to give the respective thienopyrimidines (3a,b), which reacted with phosphoryl chloride and hydrazine hydrate to afford the respective pyrimidinohydrazines (4a,b). Compound 4a condensed with acetophenone under Vilsmeier conditions to afford the formylated pyrazolopyrimidine 6. Condensation of 4a with active methylenes produced the respective pyrazolopyrimidines (7-11). Besides, 4a condensed with succinic anhydride and with phthalic anhydride, yielding the pyrrolidine-2,5-dione 12 and the isoindoline-1,3-dione 13, respectively. Moreover, 4a reacted with isatin to afford the hydrazono-indolin-2-one 14. Structural elucidations for the new thienopyrimidines were based upon compatible analytical and spectroscopic results. Eleven of the new compounds were tested and found active against influenza A neuraminidase virus (H3N2). Compounds 12 and 13 were the most potent.
DOI: 10.1002/ardp.201500407
PubMed: 26806115
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000D13
- to stream PubMed, to step Curation: 000D13
- to stream PubMed, to step Checkpoint: 000C16
- to stream Ncbi, to step Merge: 002B88
- to stream Ncbi, to step Curation: 002B88
- to stream Ncbi, to step Checkpoint: 002B88
- to stream Main, to step Merge: 000F74
- to stream Main, to step Curation: 000F72
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">New Potent SARS-CoV 3C-Like Protease Inhibitors Derived from Thieno[2,3-d]-pyrimidine Derivatives.</title><author><name sortKey="Abd El All, Amira S" sort="Abd El All, Amira S" uniqKey="Abd El All A" first="Amira S" last="Abd El-All">Amira S. Abd El-All</name><affiliation wicri:level="1"><nlm:affiliation>Department of Natural and Microbial Products, Research Division of Pharmaceutical and Drug Industries, National Research Centre, Dokki, Giza, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Department of Natural and Microbial Products, Research Division of Pharmaceutical and Drug Industries, National Research Centre, Dokki, Giza</wicri:regionArea><wicri:noRegion>Giza</wicri:noRegion></affiliation></author><author><name sortKey="Atta, Sanaa M Sh" sort="Atta, Sanaa M Sh" uniqKey="Atta S" first="Sanaa M Sh" last="Atta">Sanaa M Sh Atta</name><affiliation wicri:level="1"><nlm:affiliation>Department of Natural and Microbial Products, Research Division of Pharmaceutical and Drug Industries, National Research Centre, Dokki, Giza, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Department of Natural and Microbial Products, Research Division of Pharmaceutical and Drug Industries, National Research Centre, Dokki, Giza</wicri:regionArea><wicri:noRegion>Giza</wicri:noRegion></affiliation></author><author><name sortKey="Roaiah, Hanaa M F" sort="Roaiah, Hanaa M F" uniqKey="Roaiah H" first="Hanaa M F" last="Roaiah">Hanaa M F. Roaiah</name><affiliation wicri:level="1"><nlm:affiliation>Department of Natural and Microbial Products, Research Division of Pharmaceutical and Drug Industries, National Research Centre, Dokki, Giza, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Department of Natural and Microbial Products, Research Division of Pharmaceutical and Drug Industries, National Research Centre, Dokki, Giza</wicri:regionArea><wicri:noRegion>Giza</wicri:noRegion></affiliation></author><author><name sortKey="Awad, Enas M" sort="Awad, Enas M" uniqKey="Awad E" first="Enas M" last="Awad">Enas M. Awad</name><affiliation wicri:level="1"><nlm:affiliation>Department of Natural and Microbial Products, Research Division of Pharmaceutical and Drug Industries, National Research Centre, Dokki, Giza, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Department of Natural and Microbial Products, Research Division of Pharmaceutical and Drug Industries, National Research Centre, Dokki, Giza</wicri:regionArea><wicri:noRegion>Giza</wicri:noRegion></affiliation></author><author><name sortKey="Abdalla, Mohamed M" sort="Abdalla, Mohamed M" uniqKey="Abdalla M" first="Mohamed M" last="Abdalla">Mohamed M. Abdalla</name><affiliation wicri:level="1"><nlm:affiliation>Research Unit, Saco Pharm. Co., 6 October City, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Research Unit, Saco Pharm. Co., 6 October City</wicri:regionArea><wicri:noRegion>6 October City</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26806115</idno><idno type="pmid">26806115</idno><idno type="doi">10.1002/ardp.201500407</idno><idno type="wicri:Area/PubMed/Corpus">000D13</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000D13</idno><idno type="wicri:Area/PubMed/Curation">000D13</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000D13</idno><idno type="wicri:Area/PubMed/Checkpoint">000C16</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000C16</idno><idno type="wicri:Area/Ncbi/Merge">002B88</idno><idno type="wicri:Area/Ncbi/Curation">002B88</idno><idno type="wicri:Area/Ncbi/Checkpoint">002B88</idno><idno type="wicri:Area/Main/Merge">000F74</idno><idno type="wicri:Area/Main/Curation">000F72</idno><idno type="wicri:Area/Main/Exploration">000F72</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">New Potent SARS-CoV 3C-Like Protease Inhibitors Derived from Thieno[2,3-d]-pyrimidine Derivatives.</title><author><name sortKey="Abd El All, Amira S" sort="Abd El All, Amira S" uniqKey="Abd El All A" first="Amira S" last="Abd El-All">Amira S. Abd El-All</name><affiliation wicri:level="1"><nlm:affiliation>Department of Natural and Microbial Products, Research Division of Pharmaceutical and Drug Industries, National Research Centre, Dokki, Giza, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Department of Natural and Microbial Products, Research Division of Pharmaceutical and Drug Industries, National Research Centre, Dokki, Giza</wicri:regionArea><wicri:noRegion>Giza</wicri:noRegion></affiliation></author><author><name sortKey="Atta, Sanaa M Sh" sort="Atta, Sanaa M Sh" uniqKey="Atta S" first="Sanaa M Sh" last="Atta">Sanaa M Sh Atta</name><affiliation wicri:level="1"><nlm:affiliation>Department of Natural and Microbial Products, Research Division of Pharmaceutical and Drug Industries, National Research Centre, Dokki, Giza, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Department of Natural and Microbial Products, Research Division of Pharmaceutical and Drug Industries, National Research Centre, Dokki, Giza</wicri:regionArea><wicri:noRegion>Giza</wicri:noRegion></affiliation></author><author><name sortKey="Roaiah, Hanaa M F" sort="Roaiah, Hanaa M F" uniqKey="Roaiah H" first="Hanaa M F" last="Roaiah">Hanaa M F. Roaiah</name><affiliation wicri:level="1"><nlm:affiliation>Department of Natural and Microbial Products, Research Division of Pharmaceutical and Drug Industries, National Research Centre, Dokki, Giza, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Department of Natural and Microbial Products, Research Division of Pharmaceutical and Drug Industries, National Research Centre, Dokki, Giza</wicri:regionArea><wicri:noRegion>Giza</wicri:noRegion></affiliation></author><author><name sortKey="Awad, Enas M" sort="Awad, Enas M" uniqKey="Awad E" first="Enas M" last="Awad">Enas M. Awad</name><affiliation wicri:level="1"><nlm:affiliation>Department of Natural and Microbial Products, Research Division of Pharmaceutical and Drug Industries, National Research Centre, Dokki, Giza, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Department of Natural and Microbial Products, Research Division of Pharmaceutical and Drug Industries, National Research Centre, Dokki, Giza</wicri:regionArea><wicri:noRegion>Giza</wicri:noRegion></affiliation></author><author><name sortKey="Abdalla, Mohamed M" sort="Abdalla, Mohamed M" uniqKey="Abdalla M" first="Mohamed M" last="Abdalla">Mohamed M. Abdalla</name><affiliation wicri:level="1"><nlm:affiliation>Research Unit, Saco Pharm. Co., 6 October City, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Research Unit, Saco Pharm. Co., 6 October City</wicri:regionArea><wicri:noRegion>6 October City</wicri:noRegion></affiliation></author></analytic><series><title level="j">Archiv der Pharmazie</title><idno type="eISSN">1521-4184</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (chemical synthesis)</term><term>Antiviral Agents (chemistry)</term><term>Cysteine Endopeptidases (chemistry)</term><term>Influenza A Virus, H3N2 Subtype (enzymology)</term><term>Neuraminidase (antagonists & inhibitors)</term><term>Neuraminidase (chemistry)</term><term>Pyrimidines (chemical synthesis)</term><term>Pyrimidines (chemistry)</term><term>Structure-Activity Relationship</term><term>Viral Proteins (antagonists & inhibitors)</term><term>Viral Proteins (chemistry)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antiviraux ()</term><term>Antiviraux (synthèse chimique)</term><term>Cysteine endopeptidases ()</term><term>Protéines virales ()</term><term>Protéines virales (antagonistes et inhibiteurs)</term><term>Pyrimidines ()</term><term>Pyrimidines (synthèse chimique)</term><term>Relation structure-activité</term><term>Sialidase ()</term><term>Sialidase (antagonistes et inhibiteurs)</term><term>Sous-type H3N2 du virus de la grippe A (enzymologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Neuraminidase</term><term>Viral Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemical synthesis" xml:lang="en"><term>Antiviral Agents</term><term>Pyrimidines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Antiviral Agents</term><term>Cysteine Endopeptidases</term><term>Neuraminidase</term><term>Pyrimidines</term><term>Viral Proteins</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Protéines virales</term><term>Sialidase</term></keywords><keywords scheme="MESH" qualifier="enzymologie" xml:lang="fr"><term>Sous-type H3N2 du virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="enzymology" xml:lang="en"><term>Influenza A Virus, H3N2 Subtype</term></keywords><keywords scheme="MESH" qualifier="synthèse chimique" xml:lang="fr"><term>Antiviraux</term><term>Pyrimidines</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Structure-Activity Relationship</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Antiviraux</term><term>Cysteine endopeptidases</term><term>Protéines virales</term><term>Pyrimidines</term><term>Relation structure-activité</term><term>Sialidase</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">2-Amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxamide (1) condensed with carbaldehydes 2a,b to give the respective thienopyrimidines (3a,b), which reacted with phosphoryl chloride and hydrazine hydrate to afford the respective pyrimidinohydrazines (4a,b). Compound 4a condensed with acetophenone under Vilsmeier conditions to afford the formylated pyrazolopyrimidine 6. Condensation of 4a with active methylenes produced the respective pyrazolopyrimidines (7-11). Besides, 4a condensed with succinic anhydride and with phthalic anhydride, yielding the pyrrolidine-2,5-dione 12 and the isoindoline-1,3-dione 13, respectively. Moreover, 4a reacted with isatin to afford the hydrazono-indolin-2-one 14. Structural elucidations for the new thienopyrimidines were based upon compatible analytical and spectroscopic results. Eleven of the new compounds were tested and found active against influenza A neuraminidase virus (H3N2). Compounds 12 and 13 were the most potent. </div></front></TEI><affiliations><list><country><li>Égypte</li></country></list><tree><country name="Égypte"><noRegion><name sortKey="Abd El All, Amira S" sort="Abd El All, Amira S" uniqKey="Abd El All A" first="Amira S" last="Abd El-All">Amira S. Abd El-All</name></noRegion><name sortKey="Abdalla, Mohamed M" sort="Abdalla, Mohamed M" uniqKey="Abdalla M" first="Mohamed M" last="Abdalla">Mohamed M. Abdalla</name><name sortKey="Atta, Sanaa M Sh" sort="Atta, Sanaa M Sh" uniqKey="Atta S" first="Sanaa M Sh" last="Atta">Sanaa M Sh Atta</name><name sortKey="Awad, Enas M" sort="Awad, Enas M" uniqKey="Awad E" first="Enas M" last="Awad">Enas M. Awad</name><name sortKey="Roaiah, Hanaa M F" sort="Roaiah, Hanaa M F" uniqKey="Roaiah H" first="Hanaa M F" last="Roaiah">Hanaa M F. Roaiah</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F72 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000F72 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:26806115
|texte= New Potent SARS-CoV 3C-Like Protease Inhibitors Derived from Thieno[2,3-d]-pyrimidine Derivatives.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26806115" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |